Shopping Cart 0
Cart Subtotal
USD 0

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Hepatocyte Growth Factor-Pipeline Review, H2 2018'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 14 molecules.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor-Pipeline Review, H2 2018' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 3 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders which include indications Amyotrophic Lateral Sclerosis, Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Alzheimer's Disease, Gastric Cancer, Melanoma, Myocardial Infarction, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced Malignancy, Angina (Angina Pectoris), Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Metastatic Cancer, Nasopharyngeal Cancer, Parkinson's Disease, Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Companies Involved in Therapeutics Development

AnGes Inc

F-star Biotechnology Ltd

Kringle Pharma Inc

M3 Biotechnology Inc

Minerva Biotechnologies Corp

Molecular Partners AG

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Drug Profiles

beperminogene perplasmid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy 1 to Activate HGF for Myocardial Infarction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDX-1017-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Product Development Milestones

Featured News & Press Releases

Aug 20, 2018: Genopis builds team of experts to operate San Diego DNA production facility

Aug 01, 2018: ViroMed picks Sunyoung Kim, the founder and co-CEO, as sole chief executive

Jul 30, 2018: ViroMed announces publication on VM202's MoA in regulating muscle atrophy

Jul 27, 2018: Last patient randomized in ViroMed's VM202 phase III trial on PDPN

Jun 28, 2018: Drug based on ViroMed's VM202 Technology Successfully Completes Phase II for Critical Limb Ischemia in China

Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm

May 30, 2018: ViroMed Announces Publication of VM202s MoA in Nerve Regeneration

May 23, 2018: VM BioPharma Presents at Pain Therapeutics Conference in UK

May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018

Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin

Apr 17, 2018: ViroMed Announces Publication of VM202's MoA in Reducing Neuropathic Pain

Apr 17, 2018: ViroMeds DPN Clinical Trial Passes 70% Point in Patient Randomization

Apr 12, 2018: AARP Calls ViroMed's VM202 Hope for Peripheral Neuropathy

Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AnGes Inc, H2 2018

Pipeline by F-star Biotechnology Ltd, H2 2018

Pipeline by Kringle Pharma Inc, H2 2018

Pipeline by M3 Biotechnology Inc, H2 2018

Pipeline by Minerva Biotechnologies Corp, H2 2018

Pipeline by Molecular Partners AG, H2 2018

Pipeline by ViroMed Co Ltd, H2 2018

Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018

Pipeline by Yooyoung Pharm Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutic Products under Development, Key Players in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutics, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline Overview, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline Assessment


Companies

AnGes Inc

F-star Biotechnology Ltd

Kringle Pharma Inc

M3 Biotechnology Inc

Minerva Biotechnologies Corp

Molecular Partners AG

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd